Customize your JAMA Network experience by selecting one or more topics from the list below.
In the Editorial entitled “Screening for Prostate Cancer: Is the Third Trial the Charm?”1 published in the March 6, 2018, issue of JAMA, an incorrect age range was reported twice. In the first paragraph, the third sentence should be “In this cluster randomized trial, 573 primary care practices in the United Kingdom offered men aged 50 to 69 years a single PSA screening test or usual care.” In the fifth paragraph, the second sentence should be “Based on the CAP results, an offer of a single PSA screen in a population of men aged 50 to 69 years is ineffective, and given the higher risk of a prostate cancer diagnosis this approach engenders, likely does more harm than good.” This article was corrected online.
Incorrect Age Range. JAMA. 2018;319(14):1510. doi:10.1001/jama.2018.3290